ExpediteBio, AVS Bio team up on integrated antibody development

ExpediteBio and AVS Bio announced a strategic partnership on July 1, 2026, to combine antibody discovery, developability assessment, cell line development and process development into one workflow. The companies say the integrated service is designed to help drug developers cut risk and move preclinical antibody programs toward manufacturing readiness faster.

Why it matters: - The partnership gives antibody developers a single workflow from early discovery to small-scale batch manufacturing. - The companies are targeting one of the biggest pain points in biologics: choosing candidates early that can still be made efficiently at scale later. - The service is meant to reduce rework, development risk and delays before preclinical and clinical stages.

What happened: - ExpediteBio B.V. and AVS Bio Netherlands B.V. announced a strategic collaboration on July 1, 2026. - The agreement combines ExpediteBio’s developability-driven biologics development and manufacturing expertise with AVS Bio’s antibody discovery, engineering and protein production capabilities. - The companies said the collaboration is designed to accelerate development of antibody-based therapeutics. - The partnership is based in Utrecht and Oss, the Netherlands.

The details: - The integrated service package covers early selection of developable lead antibodies. - The workflow includes cell line development strategies compatible with fed-batch and intensified continuous processing. - The partnership includes upstream and downstream process development for early-phase toxicology and preclinical studies. - The service is intended to keep programs scalable for later-stage clinical and commercial manufacturing. - Small-scale process models are part of the offering to bridge early development and large-scale production requirements. - The companies said the approach allows future manufacturing requirements to be considered at the earliest stages of antibody development. - Debby Vermeer, chief strategic alliances at ExpediteBio, said the collaboration helps developers make better-informed decisions from the outset and align candidates with robust and scalable manufacturing strategies. - Richard van Rijnsoever, CEO of ExpediteBio, said the partnership is designed to reduce development risk and speed the path from discovery to clinical readiness. - Ilse Roodink, chief scientific officer of AVS Bio Netherlands B.V., said the extended service package complements AVS Bio’s diversity-driven decision-making approach. - Jac Price, CEO of AVS Bio, said early antibody selection is one of the highest-leverage decisions in biologics development and that combining discovery, developability and process development creates a meaningful advantage at the preclinical stage.

Between the lines: - The partnership reflects a broader push in biologics to bake manufacturability into discovery instead of fixing problems later. - That approach can matter most for preclinical programs, where candidate selection shapes timelines, cost and the odds of moving forward. - The collaboration also positions both companies as end-to-end partners rather than point-service providers.

What’s next: - ExpediteBio and AVS Bio said they aim to set a new standard for antibody development by aligning scientific innovation with manufacturing readiness from the earliest stages. - The companies will market the combined service package to antibody and biologics developers seeking faster and lower-risk progression toward clinical evaluation.

The bottom line: - The deal is about collapsing the gap between discovery and manufacturing, giving antibody developers a more integrated path to preclinical advancement.